Mr. Baker has over 25 years of executive, operational and commercial experience in the pharma industry. He has been directly involved with the commercialization of five medications with annual sales in excess of $1 billion each, including Adderall XR® and Vyvanse®, the two most successful ADHD brands.
Previously, he was the Chief Commercial Officer and interim CEO of Alcobra Ltd., a CNS specialty pharma company. He worked at Shire for 10 years as Vice President of Commercial Strategy & New Business in the Neuroscience Business Unit, Global General Manager for Vyvanse® and Vice President, ADHD Marketing.
Prior to Shire, he worked at Merck in marketing, sales, market research, and business development. Mr. Baker's therapeutic expertise includes ADHD, autism, osteoporosis, migraine, and hyperlipidemia.
Mr. Baker earned a bachelor’s degree in Economics and Computer Science from Duke University and and an MBA from Duke's Fuqua School of Business.